Literature DB >> 30367283

Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits.

Dan P Zandberg1, Robert L Ferris2.   

Abstract

OPINION STATEMENT: In head and neck cancer, we continue to work towards a more personalized approach to treatment of patients, where analysis of a patient's tumor guides targeting of molecular or immunologic pathways. Critically important to this pursuit is a better understanding of the direct biologic effect of a drug or combination on the tumor microenvironment in humans, as well as biomarker discovery. These goals are consistent with the primary purpose of a "window of opportunity" trial and while conduct of these trials requires a careful balance of benefits and potential risks, to date these trials have been both feasible and safe in HNSCC in the curative intent setting. In the era of immunotherapy, with countless possible combinations and ongoing clinical trials, window trials are even more important for informing clinical trial design and appropriate combination therapy, and ultimately a more personalized approach to our patients that leads to improvement in outcomes.

Entities:  

Keywords:  Anti-PD-1; Cetuximab; HNSCC; Immunotherapy; Neoadjuvant; Targeted therapy; Window trial

Mesh:

Substances:

Year:  2018        PMID: 30367283      PMCID: PMC6564676          DOI: 10.1007/s11864-018-0587-0

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  31 in total

1.  Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.

Authors:  Gregory T Wolf; Willard E Fee; Robert W Dolan; Jeffrey S Moyer; Michael J Kaplan; Paul M Spring; James Suen; Daniel E Kenady; Jason G Newman; William R Carroll; M Boyd Gillespie; Scott M Freeman; Lorraine Baltzer; Terry D Kirkley; Harvey J Brandwein; John W Hadden
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

2.  Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Authors:  Jean-Pascal H Machiels; Robert I Haddad; Jérôme Fayette; Lisa F Licitra; Makoto Tahara; Jan B Vermorken; Paul M Clement; Thomas Gauler; Didier Cupissol; Juan José Grau; Joël Guigay; Francesco Caponigro; Gilberto de Castro; Luciano de Souza Viana; Ulrich Keilholz; Joseph M Del Campo; Xiuyu Julie Cong; Eva Ehrnrooth; Ezra E W Cohen
Journal:  Lancet Oncol       Date:  2015-04-16       Impact factor: 41.316

3.  Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.

Authors:  M R Posner; J H Lorch; O Goloubeva; M Tan; L M Schumaker; N J Sarlis; R I Haddad; K J Cullen
Journal:  Ann Oncol       Date:  2011-02-11       Impact factor: 32.976

Review 4.  Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.

Authors:  Toni M Brand; Mari Iida; Deric L Wheeler
Journal:  Cancer Biol Ther       Date:  2011-05-01       Impact factor: 4.742

5.  Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.

Authors:  Raghvendra M Srivastava; Steve C Lee; Pedro A Andrade Filho; Christopher A Lord; Hyun-Bae Jie; H Carter Davidson; Andrés López-Albaitero; Sandra P Gibson; William E Gooding; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

6.  Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.

Authors:  S Schmitz; M Hamoir; H Reychler; M Magremanne; B Weynand; R Lhommel; F-X Hanin; T Duprez; N Michoux; D Rommel; M Lonneux; N Cappoen; A Gillain; J-P Machiels
Journal:  Ann Oncol       Date:  2013-05-23       Impact factor: 32.976

7.  Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.

Authors:  Sophie Postel-Vinay; Laurence Collette; Xavier Paoletti; Elisa Rizzo; Christophe Massard; David Olmos; Camilla Fowst; Bernard Levy; Pierre Mancini; Denis Lacombe; Percy Ivy; Lesley Seymour; Christophe Le Tourneau; Lillian L Siu; Stan B Kaye; Jaap Verweij; Jean-Charles Soria
Journal:  Eur J Cancer       Date:  2014-05-28       Impact factor: 9.162

8.  Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).

Authors:  J-P Machiels; P Bossi; J Menis; M Lia; C Fortpied; Y Liu; R Lhommel; M Lemort; S Schmitz; S Canevari; L De Cecco; M Guzzo; R Bianchi; P Quattrone; F Crippa; T Duprez; Y Lalami; M Quiriny; N de Saint Aubain; P M Clement; R Coropciuc; E Hauben; L F Licitra
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

Review 9.  Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.

Authors:  Robert L Ferris; Heinz-Josef Lenz; Anna Maria Trotta; Jesús García-Foncillas; Jeltje Schulten; François Audhuy; Marco Merlano; Gerard Milano
Journal:  Cancer Treat Rev       Date:  2017-12-02       Impact factor: 12.111

Review 10.  Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors.

Authors:  Assuntina G Sacco; Francis P Worden
Journal:  Onco Targets Ther       Date:  2016-04-04       Impact factor: 4.147

View more
  1 in total

1.  NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models.

Authors:  Mandy Gruijs; Sonja H Ganzevles; Marijke Stigter-van Walsum; Richard van der Mast; Monique M van Ostaijen-Ten Dam; Cornelis W Tuk; Marco W Schilham; C René Leemans; Ruud H Brakenhoff; Marjolein van Egmond; Rieneke van de Ven; Jantine E Bakema
Journal:  Int J Mol Sci       Date:  2021-10-14       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.